National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

BLP25 liposome vaccine
A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1-expressing tumor cells, resulting in growth inhibition. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein that is overexpressed on the cell surfaces of many epithelial tumor cells as well as on the cell surfaces of some B-cell lymphoma cells and multiple myeloma cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Stimuvax
Abbreviations:BP1-7-KLH
L-BLP25
Code name:BLP25



Previous:black cohosh, black tea, Blenoxane, bleomycin sulfate, blinatumomab
Next:blue citrus capsule, BMS-214662, BMS-599626, Boniva, boronophenylalanine-fructose complex

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov